Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 May 1996:
Vol. 272. no. 5262, pp. 643 - 0
DOI: 10.1126/science.272.5262.643a
Prev | Table of Contents | Next

News & Comment

Eliot Marshall

While some academic researchers have been signing a pledge not to patent raw DNA sequences, companies that specialize in sequencing DNA--chiefly Incyte Pharmaceuticals of Palo Alto, California, and Human Genome Sciences of Rockville, Maryland--have been channeling data from their automated sequencers into the Patent and Trademark Office (PTO) at a torrential rate. Applications covering more than 400,000 sequences have been filed, and the PTO is seeking help in dealing with the flood.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)